Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Brookings: Spurring Private Investment in Global Health Research and Development

1/6/2017

0 Comments

 
Washington, DC — Jake Schneider, John Villasenor, and Darrell M. West writing on the Brookings Institution’s website that access to affordable medication is an important global challenge, particularly in emerging economies.
 
In these countries, a complex set of factors have long impeded development, deployment, and affordability of much needed drugs, vaccines and diagnostic tests.
 
While there isn’t any single solution to this challenge, an important part of the overall solution lies in incentivizing investors and pharmaceutical companies to raise their investment in global health R&D.
 
A team of researchers in the Center for Technological Innovation at the Brookings Institution, in collaboration with researchers at the University of Washington’s Evans School of Public Policy and Governance, recently began a two-year project aimed at finding ways to address this investment shortfall. 
​The project recognizes the need to complement the research on the social returns to global health R&D by examining the potential financial returns to private sector global health R&D investors, and offers policy solutions that can boost those returns.
 
To tackle this challenge, we will be using a multi-pronged approach.
 
One of the key issues we will be looking at is health governance capacity—the ability of a nation’s government and institutions to implement health policies, provide medical services, and respond to global health crises.
 
We will focus specifically on a set of 18 countries in Sub-Saharan Africa and Asia, most of which are emerging economies, but some of them are not (e.g. China).
 
Investments in global health R&D will only be effective if new developments can be effectively deployed in the places where they are needed.
 
Infrastructure, economic and political stability, and the regulatory environment are some of the many factors that can maximize the benefit from global health R&D investments in a given country.
 
We will analyze these factors and build an index, to be released in March 2017, that provides a holistic evaluation of the potential impact of global health R&D in each country.
 
Our hope is that policymakers, pharmaceutical companies, regulators, and researchers will use the index to increase the scale and reach of global health R&D investments.
 
Next, we will publish a report on global health R&D spending in the summer of 2017. This analysis will build on the governance capacity findings by adding an overview of existing (largely public sector) global health R&D spending as well as a discussion of the implications of that spending within our focus countries.
 
In addition, we will use financial and economic modeling to identify new ways to encourage private sector investment in global health R&D. As part of this work, we plan to identify new structures to incentivize private sector global health R&D spending.
 
For example, we will look at potential policy changes (such as enhancements to Priority Review Vouchers) that can lead to increased private investment. More broadly, we plan to model investment opportunities for a set of structures (including advanced market commitments, insurance markets, and financial prizes) that represent a significant private sector global health R&D investment opportunity. We expect to publish the results of this analysis in winter 2017-18.
 
Other components of this project include an analysis of household survey data from a Sub-Saharan African country to examine the impact of antiretroviral therapy on employment, hours worked, and educational attainment, an estimate of market size for particular drug treatments and possible financial returns to private investors in that country, and a literature review focused on private sector global health R&D investment.
 
Global health remains one of the most pressing global challenges. Public sector investment alone is not sufficient to meet global health R&D investment needs in the coming years. The private sector has the capacity to provide substantially increased investment in this sector, but can’t be expected to do so unless there is a strong case that those investment increases will be accompanied by strong economic returns.
 
For the full story, click here.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507